Secure Telehealth System Combines Tetherless
Pulse Oximetry with a Remote Data Capture, Patient Surveillance,
and Care Flow Platform
Masimo (NASDAQ: MASI) announced today the full market release of
Masimo SafetyNet™, an innovative, economically scalable cloud-based
patient management solution designed to help clinicians care for
patients remotely in hospital settings and in non-traditional
settings and circumstances. Successfully piloted at leading
institutions like University Hospitals (UH) in Cleveland and St.
Luke’s University Health Network (St. Luke’s) in Pennsylvania and
New Jersey, Masimo SafetyNet is now available worldwide to help
clinicians and public health officials combat the global COVID-19
pandemic.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200410005060/en/
Masimo SafetyNet™ (Graphic: Business
Wire)
On Wednesday, April 15 at 8:00 am PDT, Masimo and University
Hospitals will jointly host a public webinar in which Dr. Peter
Pronovost and his colleagues at University Hospitals join Masimo
Founder and CEO Joe Kiani to discuss Masimo SafetyNet and UH’s
experience using Masimo SafetyNet to help combat COVID-19. The
webinar will cover best practices for deploying Masimo SafetyNet,
based on UH’s input and deployment of the platform, including the
protocols they developed for their teams to integrate it into their
response efforts. Clinicians and hospital staff worldwide are
invited to participate and learn how they can deploy Masimo
SafetyNet at their own institutions. Click here for more details
and to register.
Masimo SafetyNet uses a tetherless, wearable single-patient-use
SET® sensor to monitor a patient’s blood oxygen saturation and
respiration rate, as well as pulse rate, perfusion index, and PVi®,
and is designed to help manage the surge in COVID-19 patients while
maintaining distance from other patients and providers, allowing
hospitals to expand patient remote monitoring into alternative care
spaces, including overflow locations, emergency recovery
facilities, and home care settings.
The telehealth solution combines clinically proven Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry with a
cloud-based remote data capture and surveillance platform
accessible from a patient’s Android or iOS smartphone or smart
device. Monitoring key physiological data can help provide
clinicians with an accurate snapshot of a patient’s respiratory
status and facilitates awareness of the need for intervention.
“Many patients come to the hospital with COVID-19 symptoms and
often times they are admitted simply because clinicians feel the
patient would not be safe at home without regular monitoring,”
explained Peter Pronovost, MD, Chief Clinical Transformation
Officer at University Hospitals in Cleveland, Ohio. “As such, many
patients are admitted where they can potentially expose other
patients and the staff to the coronavirus. With Masimo SafetyNet,
we can now send patients home with the security of the patient and
their provider knowing their critical vital signs such as oxygen
saturation and respiration rate will be safely monitored at home.
This technology also serves as a cost-effective way to scale
monitoring and increase capacity for hospitals. We are currently
using the product in the following ways: if a patient comes to the
emergency department, but can be monitored at home rather than
admitted; for patients who are discharged from the hospital and
would still benefit from home monitoring; for patients being cared
for by home health providers; and for cancer patients with COVID
who would be at greater risk if cared for in an inpatient setting.
And daily our clinicians are thinking of new ways to apply this
technology.”
Aldo Carmona, MD, St. Luke’s Senior Vice President of Clinical
Innovation and Chairman of the Department of Anesthesia and
Critical Care, added, “I believe the collaboration of the St Luke’s
and Masimo teams during our pilot of Masimo SafetyNet will improve
the patient and provider experience. In conjunction with the Masimo
team, we created a dashboard where multiple patients can be
monitored in real time. This can be done rapidly on a floor where
no previous monitoring existed and can be monitored from any
location; alerts can go to providers in real time. After several
years of using the Masimo Patient SafetyNet™ hard-wired system to
help improve outcomes, Masimo SafetyNet was a natural solution for
our network to meet capacity challenges during this pandemic.”
In addition to COVID-19 CarePrograms, Masimo SafetyNet can be
configured for more than 150 other CarePrograms, including COPD,
heart failure, and oncology.
Joe Kiani, Founder and CEO of Masimo, said, “Masimo is proud to
be able to support the brave nurses and doctors working around the
clock to save lives across the world. We believe Masimo SafetyNet
is a key asset in the fight against COVID-19, helping clinicians
care for the extraordinary surge of patients as efficiently and
effectively as possible, both in and out of the hospital. We are
grateful for our partnerships with University Hospitals and St.
Luke’s, whose piloting and early adoption of Masimo SafetyNet is
already showing how this solution is making a difference. Everybody
from UH, St Luke’s, and Masimo has worked very hard over the past
four weeks to improve the interface so that everyone can now
benefit. In addition, we would like to thank our suppliers, Nordic
Semiconductor and Texas Instruments, for prioritizing our orders of
Masimo SafetyNet components, in volume, to help COVID-19 patients
during this difficult time.”
@MasimoInnovates | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.1 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,3 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs.4-6 Masimo SET® is estimated to be used on
more than 200 million patients in leading hospitals and other
healthcare settings around the world,7 and is the primary pulse
oximetry at 9 of the top 10 hospitals listed in the 2019-20 U.S.
News and World Report Best Hospitals Honor Roll.8 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET®
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the Iris®
platform, and include Iris Gateway®, Patient SafetyNet, Replica™,
Halo ION™, UniView™, and Masimo SafetyNet™. Additional information
about Masimo and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Taenzer AH et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for
General Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SafetyNet™ and
SET®. These forward-looking statements are based on current
expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and
many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in
our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SafetyNet and SET®, contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200410005060/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024